Clinical Trial Update: Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty [Phase 2]

View source ↗

Summary

Phase 2 study of botulinum neurotoxin serotype E (EB-001) for reducing musculoskeletal pain after abdominoplasty was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abdominoplasty-related Musculoskeletal Pain

Drugs mentioned

• EB-001 (botulinum neurotoxin serotype E) (botulinum neurotoxin serotype E)

Snippet

Sponsor: Allergan | Conditions: Abdominoplasty | Phase 2 | Status: TERMINATED | Results posted: 2019-08-05